To our knowledge, this is the first study to analyze over 660 thousand AE reports for RA indication in postmarketing data to quantify the association between TNF inhibitor monotherapy use and psoriasis. In addition, we quantified the risk of psoriasis in RA patients undergoing other types of therapeutic treatments such as IL-6 inhibitors (tocilizumab) and JAK inhibitors (tofacitinib), among others. This evidence concerns the gene IL6 and rheumatoid arthritis.